Full-Time

Specialist IS Bus Sys Analyst

Signal & Risk Management

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

No salary listed

Senior, Expert

Hyderabad, Telangana, India

Category
Data Management
Data Analysis
Data & Analytics
Required Skills
Agile
JIRA
Data Analysis
Requirements
  • Master’s degree with 4 - 6 years of experience in Computer Science, IT or related field OR
  • Bachelor’s degree with 6 - 8 years of experience in Computer Science, IT or related field OR
  • Diploma with 10 - 12 years of experience in Computer Science, IT or related field
  • 3+ years of experience COTS Pharmacovigilance Platforms (for example Argus) is a plus or other safety database.
  • Extensive expertise in SDLC, including requirements, design, testing, data analysis, change control
  • Experienced in Agile project methodologies and working in Product Teams by using JIRA Experience or demonstrable understanding of Computer Systems Validation including FDA 21 CFR Part 11, GxP Compliance, and change control
  • Strong communications skills in writing, speaking, communicating and time management skills
  • Has high learning agility, problem solving and analytical thinking
  • Has requirements gathering and process improvement experience.
Responsibilities
  • Work with partners to identify and prioritize system enhancements and new functionalities to meet evolving business needs
  • Responsible for defining and implementing a project and technical road maps that align with the strategy
  • Find opportunities for automation and process improvements within the Safety ecosystem
  • Overall accountability of technical implementation aspects of projects including planning, architecture, design, development, and testing to follow IS Change Control and GxP validation process
  • Work closely with the delivery and platform teams to ensure that the applications are aligned with approved architectural and development guidelines
  • Identify data patterns to support informed decision making. Collect analyze, and interpret data to identify trends, insights, and areas of improvement.
  • Keeps updated on industry trends, emerging trends and standard processes for pharmacovigilance systems
  • Leads and contributes to business case development, workshops, and RFP’s
  • Responsible for supporting and leading technical root cause analysis and works with vendors to resolve Pharmacovigilance systems related issues
  • Responsible for improving performance by coaching, mentorship, and training to develop both technical and professional skills within the team
  • Support audits and inspections.
Desired Qualifications
  • Ability to work in a fast-paced and dynamic environment
  • Able to communicate technical or complex subject matters in business terms
  • Outstanding written and verbal communication skills, and ability to explain technical concepts to non-technical clients
  • Experience with Safety Signal and Risk Management platforms is a plus
  • Experienced in database programming languages, data modelling concepts, including Oracle SQL and PL/SQL
  • SAFe for Teams certification (preferred)

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are medicines made from living organisms. These therapies target conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care by providing effective treatments for serious health conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Micromet boosts Amgen's oncology portfolio with BiTE antibody blinatumomab.
  • Institutional investments indicate strong confidence in Amgen's financial health and prospects.
  • Amgen's AI-driven drug discovery investments could accelerate R&D capabilities.

What critics are saying

  • Micromet acquisition may face clinical or regulatory challenges impacting strategic goals.
  • Investor pressure for short-term gains may affect long-term R&D investments.
  • FTC scrutiny on mergers could hinder Amgen's future strategic growth.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline in oncology, cardiovascular, and autoimmune disorders.
  • Amgen's strategic acquisitions enhance its innovative medicine portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Amgen
Jun 2nd, 2025
Amgen to Acquire Micromet| Amgen

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.